Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $20 to $22.